- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06714591
Uno studio clinico di fase I multicentrico, in aperto per valutare la sicurezza, la tollerabilità, il profilo farmacocinetico e l'efficacia preliminare di BL-M11D1 in pazienti con leucemia mieloide acuta recidivante/refrattaria
Uno studio clinico di fase I multicentrico, in aperto per valutare la sicurezza, la tollerabilità, il profilo farmacocinetico e l'efficacia preliminare di BL-M11D1 in pazienti con leucemia mieloide acuta recidivante/refrattaria.
The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
BL-M11D1-HM-101 is a multi-center, Phase 1 study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.
This study will be conducted in two parts (dose escalation, and dose finding). Cohort A will be dosed on Days 1, 8,15 of a continuous 28-day treatment cycle. The cohort has different dose groups. Cohort B will be dosed on Days 1, 4, 7 or 8 of a continuous 28-day treatment cycle. The cohorts have different dose groups.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
California
-
Duarte, California, Stati Uniti, 91010
- City of Hope
-
Los Angeles, California, Stati Uniti, 90095
- UCLA Ronald Reagan Medical Center
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- University of Colorado Anschutz Medical Campus
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06511
- Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven
-
-
Florida
-
Tampa, Florida, Stati Uniti, 33612
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern Memorial Hospital
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Michigan
-
Grand Rapids, Michigan, Stati Uniti, 49546
- START Midwest/The Cancer and Hematology Center
-
-
New Jersey
-
Hackensack, New Jersey, Stati Uniti, 07601
- John Theurer Cancer Center-Hackensack
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45236
- Oncology Hematology Care Clinical Trials, LLC
-
Columbus, Ohio, Stati Uniti, 43210
- The Ohio State University Comprehensive Cancer Center
-
-
Oregon
-
Eugene, Oregon, Stati Uniti, 24224
- WVCI Oncology Associates of Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19111
- Temple Health Fox Chase Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- SCRI -TriStar BMT
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- MD Anderson Cancer Center
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Virginia Cancer Specialists
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98109
- Fred Hutchinson Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Signed the informed consent
- Age ≥18 years
- Has a life expectancy of ≥3 months
- Relapsed and/or refractory CD33-positive AML as determined by local pathology review that has failed initial standard of care therapy. Diagnosis of primary AML or AML secondary to myelodysplastic syndromes. Relapsed or refractory status. CD33-positive as confirmed by local flow cytometry or cytology
- Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2
- Toxicity of previous anticancer therapy has returned to Grade ≤1 as defined by NCI CTCAE V5.0, except for alopecia and endocrinopathies controlled by replacement therapy that must be Grade ≤2
- Has adequate liver and renal function before registration, defined as: a. Hepatic function: Total bilirubin (TBIL) ≤1.5×ULN (≤3×ULN for subjects with Gilbert's syndrome), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN b. Renal function: Creatinine clearance ≥50 mL/min (Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration [CKD-Epi], or Modification of Diet in Renal Disease Study [MDRD] equations)
- Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception during the course of the study and for 7 months after the last dose of study treatment. An additional contraceptive method, such as a barrier method (eg, condom), is recommended
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and must be nonlactating
Exclusion Criteria:
-
Subjects with acute promyelocytic leukemia (APL) or chronic myelogenous leukemia in blast crisis (CML)
-
Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major surgery, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other anticancer therapy within 2 weeks) prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration, or palliative radiotherapy within 2 weeks prior to the first administration
-
Subjects with history of severe heart disease, such as symptomatic congestive heart failure (CHF) ≥ Grade 2 (CTCAE 5.0), New York Heart Association (NYHA) ≥ Grade 2 heart failure, history of transmural myocardial infarction, unstable cardiac arrhythmias or angina pectoris within 6 months before screening
-
Subjects with prolonged QT interval (QTcF >470 msec), complete left bundle branch block, Grade 3 atrioventricular block or a history of additional risk factors for Torsades de Pointes (TdP; eg, heart failure as defined in Exclusion Criterion 3, chronic or recurrent hypokalemia that requires medical intervention, congenital long QT syndrome, family history of long QT syndrome) or any current concomitant medication known to prolong the QT/QTc interval or cause TdP
-
Active autoimmune diseases and inflammatory diseases, such as: systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, etc., except for Type I diabetes, hypothyroidism that can be controlled only by standard of care treatment, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis)
-
Subjects with other prior or concurrent malignancies except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after adequate resection, or other malignancy treated with curative intent with as disease-free interval of at least 1 year
-
Subjects with poorly controlled hypertension or uncontrolled hypertension by two or more antihypertensive drugs (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg)
-
Subjects with active acute or chronic graft vs. host disease (aGVHD or cGVHD) should be excluded from this study. Subjects with GVHD who are receiving treatment with systemic glucocorticoids >10 mg/day equivalent of prednisone should also be excluded from the study; however, treatment with low-dose glucocorticoids (≤10 mg/day equivalent of prednisone) is permitted
-
Subjects currently receiving immunosuppressive therapy should be excluded from this study.
-
Clinical evidence of disseminated intravascular coagulation (DIC). Smoldering low grade DIC is allowed after discussion with the sponsor
-
Subjects with stroke or transient ischemic attack (TIA) within 6 months before screening
-
Subjects with a thromboembolic event (eg, deep vein thrombosis [DVT] or pulmonary embolism [PE]) within 6 months before screening except for those who are clinically stable and receiving treatment with adequate anticoagulant therapy for at least 3 weeks before screening
-
Subjects with active central nervous system (CNS) AML will be excluded. A lumbar puncture does not need to be performed unless there is clinical suspicion of CNS involvement per investigator judgment. Concurrent therapy for CNS prophylaxis or continuation of therapy for controlled CNS AML is allowed with the approval of the sponsor
-
Subjects with pre-existing ≥Grade 2 peripheral neuropathy
-
Subjects with advanced/ clinically significant lung diseases, such as poorly controlled COPD and asthma, restrictive lung disease, pulmonary hypertension etc.
-
Subjects who have a history of noninfectious interstitial lung disease (ILD)/ pneumonitis that required treatment with steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening
-
Subjects who have a history of anaphylaxis or severe hypersensitivity to recombinant humanized antibodies or human-mouse chimeric antibodies or any of the components of BL-M11D1
-
Subjects with known human immunodeficiency virus infection (HIV Ab positive) Subjects are allowed to participate if all of the following criteria are met: (1) Undetectable HIV RNA and CD4 count ≥350 cells/μL at screening, (2) No AIDS defining opportunistic infection within 12 months prior to screening, (3) On stable antiretroviral therapy (ART) for at least 4 weeks prior to screening with projected continuation of ART as clinically indicated while on the study
-
Subjects with active Hepatitis B virus (HBV) infection (positive HBsAg test). Subjects with chronic inactive HBV infection are eligible if they meet all of the following criteria:
- Have a HBV DNA viral load ≤ 500 IU/mL
- Have normal AST and ALT, OR if liver involvement is present, has AST and ALT <3 × ULN which are not attributed to HBV infection
- on antiviral treatment, as clinically indicated
-
Subjects with active Hepatitis C virus (HCV) infection (HCV antibody positive and HCV-RNA > the lower limit of detection). Subjects with a positive anti-HCV antibody are eligible only if PCR is negative for HCV RNA
-
Subjects with active or latent tuberculosis
-
Subjects with active and uncontrolled infections requiring IV antibiotic, antiviral, or antifungal treatment, such as severe pneumonia, bacteremia, sepsis, etc., within 1 week prior to first dose of study treatment. Subjects on stable oral antimicrobials with no clinical or laboratory evidence of active infection are eligible
-
Received an investigational drug within 2 weeks prior to first dose of study treatment.
-
Subjects who are pregnant, breastfeeding, or planning to become pregnant during the study
-
Prior treatment with a topoisomerase inhibitor-based antibody-drug conjugate (ADC.)
-
Previous history of significant gastrointestinal conditions, including Grade 3 or higher diarrhea, colitis, gastrointestinal bleeding and history of major gastrointestinal surgeries
28. Progressed on more than 2 different lines of systemic cytotoxic therapies; patients with 3 prior lines of systemic cytotoxic therapy or with prior allogeneic stem cell transplant may be enrolled upon consultation and approval from the sponsor
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Experimental: Cohort A BL-M11D1 administered Days 1, 8 and 15 in 28-day cycle
Cohort A: BL-M11D1 will be administered on Days 1, 8 and 15 by intravenous infusion every 28 days. |
The study includes 2 parts: Part 1 Dose escalation and Dose Finding |
|
Sperimentale: Experimental: Cohort B BL-M11D1 administered Days 1, 4 7 or 8 in 28-day cycle
Cohort B: BL-M11D1 will be administered on Days 1,4, 7 or 8 by intravenous infusion every 28 days. |
The study includes 2 parts: Part 1 Dose escalation and Dose Finding |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Participants with dose-limiting toxicities
Lasso di tempo: 1 Year
|
DLTs are defined as any of the following events that are not clearly due to the underlying disease, disease progression, or extraneous causes:
|
1 Year
|
|
Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs)
Lasso di tempo: 1 Year
|
Measuring the number of patients with serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs) |
1 Year
|
|
To determine the minimum safe and effective dose (MSED), maximum tolerated dose (MTD) if reached, and maximum administered dose (MAD) of BL-M11D1 in AML
Lasso di tempo: 1 Year
|
Determine the highest BL-M11D1 dose level at which ≤33% subjects experience a DLT during the DLT evaluation period and highest BL-M11D1 dose administered in the event and MTD cannot be defined. |
1 Year
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Cmax of BL-M11D1
Lasso di tempo: 1 Year
|
Calculate maximum (peak) observed concentration of BL-M11D1 |
1 Year
|
|
Tmax of BL-M11D1
Lasso di tempo: 1 Year
|
Calculate time of maximum observed concentration of BL-M1D1 |
1 Year
|
|
Tmax of free payload ED-04
Lasso di tempo: 1 Year
|
Calculate time of maximum observed concentration of free payload ED-04 |
1 Year
|
|
Cmax of free payload ED-04
Lasso di tempo: 1 Year
|
Calculate maximum (peak) observed concentration of free payload ED-04 |
1 Year
|
|
AUC(0-8) of BL-M11D1
Lasso di tempo: 1 Year
|
Calculate area under the serum concentration-time curve of BL-M11D1 from time 0 to 8 hours |
1 Year
|
|
AUC(0-8) of free payload ED-04
Lasso di tempo: 1 Year
|
Calculate area under the serum concentration-time curve of free payload ED-04 from time 0 to 8 hours |
1 Year
|
|
AUC(last) of BL-BM11D1
Lasso di tempo: 1 Year
|
Calculate area under the serum concentration-time curve up of BL-M11D1 to the last quantifiable time |
1 Year
|
|
AUC(last) of free payload ED-04
Lasso di tempo: 1 Year
|
Calculate area under the serum concentration-time curve up of free payload ED-04 to the last quantifiable time |
1 Year
|
|
Tmax of anti-CD33 antibody
Lasso di tempo: 1 Year
|
Calculate time of maximum observed concentration of anti-CD33 antibody |
1 Year
|
|
AUC (0-8) of anti-CD33 antibodies
Lasso di tempo: 1 Year
|
Calculate area under the serum concentration-time curve of anti-CD33 antibodies from time 0 to 8 hours |
1 Year
|
|
AUC (last) anti-CD33 antibodies
Lasso di tempo: 1 Year
|
Calculate area under the serum concentration-time curve up of anti-CD33 antibodies to the last quantifiable time |
1 Year
|
|
Overall Response Rate (ORR)
Lasso di tempo: 1 Year
|
To assess the clinical efficacy of BL-M11D1 as measured by ORR using RECIST criteria v 1.1 |
1 Year
|
|
Duration of response (DOR)
Lasso di tempo: 1 Year
|
To access the clinical efficacy of BL-M11D1 as measured by DOR using RECIST criteria 1.1 |
1 Year
|
|
Complete Remission (CR)
Lasso di tempo: 1 Year
|
To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria. |
1 Year
|
|
CR with partial hematologic recovery (CRh)
Lasso di tempo: 1 Year
|
To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria. |
1 Year
|
|
CR with incomplete hematologic recovery (CRi)
Lasso di tempo: 1 Year
|
To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria. |
1 Year
|
|
CR/CRi, CRs with or without measurable residual disease (MRD)
Lasso di tempo: 1 Year
|
To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria. |
1 Year
|
|
morphologic leukemia-free state (MLFS)
Lasso di tempo: 1 Year
|
To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria. |
1 Year
|
|
partial remission (PR)
Lasso di tempo: 1 Year
|
To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria. |
1 Year
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Olu Lawson, SystImmune Inc.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- BL-M11D1-HM-101
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .